Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 12, 2024

SELL
$161.01 - $317.85 $6.18 Million - $12.2 Million
-38,378 Reduced 16.85%
189,340 $59.9 Million
Q3 2023

Oct 27, 2023

BUY
$164.66 - $218.08 $13.1 Million - $17.3 Million
79,291 Added 53.42%
227,718 $38.5 Million
Q2 2023

Aug 09, 2023

BUY
$176.32 - $240.22 $1.5 Million - $2.04 Million
8,492 Added 6.07%
148,427 $32.2 Million
Q1 2023

May 10, 2023

BUY
$161.33 - $204.36 $6.33 Million - $8.02 Million
39,254 Added 38.99%
139,935 $25.4 Million
Q4 2022

Feb 06, 2023

BUY
$191.53 - $236.82 $4.58 Million - $5.66 Million
23,900 Added 31.13%
100,681 $19.8 Million
Q3 2022

Nov 07, 2022

BUY
$123.79 - $277.42 $4.56 Million - $10.2 Million
36,810 Added 92.09%
76,781 $17.2 Million
Q2 2022

Aug 04, 2022

SELL
$93.97 - $143.33 $610,805 - $931,645
-6,500 Reduced 13.99%
39,971 $5.06 Million
Q1 2022

May 10, 2022

SELL
$98.9 - $132.37 $76,746 - $102,719
-776 Reduced 1.64%
46,471 $5.89 Million
Q4 2021

Feb 10, 2022

BUY
$110.64 - $159.4 $811,765 - $1.17 Million
7,337 Added 18.38%
47,247 $6.19 Million
Q3 2021

Nov 09, 2021

BUY
$101.2 - $125.87 $192,280 - $239,153
1,900 Added 5.0%
39,910 $4.88 Million
Q2 2021

Aug 11, 2021

BUY
$107.45 - $135.95 $106,590 - $134,862
992 Added 2.68%
38,010 $4.34 Million
Q1 2021

May 14, 2021

BUY
$95.46 - $133.08 $819,142 - $1.14 Million
8,581 Added 30.18%
37,018 $4.45 Million
Q3 2020

Nov 10, 2020

BUY
$71.31 - $109.74 $106,965 - $164,610
1,500 Added 5.57%
28,437 $2.2 Million
Q2 2020

Aug 13, 2020

BUY
$62.14 - $117.21 $37,284 - $70,326
600 Added 2.28%
26,937 $3 Million
Q1 2020

May 15, 2020

SELL
$60.41 - $115.92 $24,164 - $46,368
-400 Reduced 1.5%
26,337 $1.9 Million
Q4 2019

Feb 11, 2020

BUY
$11.44 - $123.99 $43,540 - $471,905
3,806 Added 16.6%
26,737 $2.01 Million
Q3 2019

Nov 07, 2019

BUY
$16.05 - $27.35 $368,042 - $627,162
22,931 New
22,931 $374,000

Others Institutions Holding KRTX

About Karuna Therapeutics, Inc.


  • Ticker KRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,965,000
  • Description
  • Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...
More about KRTX
Track This Portfolio

Track Td Asset Management Inc Portfolio

Follow Td Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.